短联律间期室颤患者存在靶向TREK-1的循环自身抗体
该前瞻性单中心病例对照研究纳入2019至2023年加拿大魁北克地区14例短联律间期室颤(SCVF)患者、19例特发性室颤(IVF)患者及38例健康对照,采用肽微阵列技术筛查靶向心脏离子通道的自身抗体。结果显示50%的SCVF患者存在抗TREK-1自身抗体(P=0.049),膜片钳实验证实该抗体可激活TREK-1通道,且该效应可被奎尼丁拮抗。
要点
- SCVF患者中抗TREK-1自身体检出率达50%,显著高于对照(P=0.049)。
- 抗TREK-1自身抗体可激活TREK-1通道,奎尼丁可拮抗该效应。
- 抗TREK-1自身抗体是首个报道的SCVF生物标志物,提示自身免疫参与致心律失常。
核心结论
- SCVF患者携带靶向心脏TREK-1通道的循环自身抗体,该抗体具有通道激活特性并可能直接参与SCVF的致心律失常机制。
研究设计与样本
- 前瞻性单中心病例对照研究,纳入2019至2023年加拿大魁北克大学拉瓦尔遗传性心律失常门诊的SCVF或IVF心脏骤停幸存者。
- SCVF患者14例(女性4例,占29%;中位年龄45岁,IQR 36-59;非西班牙裔白人14例,占100%)。
- IVF患者19例(女性8例,占42%;中位年龄49岁,IQR 38-57;非西班牙裔白人19例,占100%)。
- 健康对照38例(女性20例,占53%;中位年龄45岁,IQR 29-66;非西班牙裔白人36例,占95%),按性别、年龄和种族匹配。
- 采用肽微阵列技术筛查血浆中靶向心脏离子通道的自身抗体,并从混合血浆样本中纯化目标自身抗体用于后续细胞电生理研究。
主要发现
- SCVF患者中7例(50%)检出靶向心脏TREK-1的自身抗体(P=0.049)。
- 研究期间11例(79%)SCVF先证者在中位4.3个月(IQR 0.3-20.7)后出现室颤复发。
- 膜片钳实验显示抗TREK-1自身抗体在HEK293细胞和人诱导多能干细胞来源心肌细胞中均具有通道激活特性,该效应可被奎尼丁拮抗。
临床怎么用
- 抗TREK-1自身抗体可作为SCVF的首个候选生物标志物,有助于提高SCVF的识别与诊断。
- 抗TREK-1自身抗体的通道激活效应可被奎尼丁拮抗,提示奎尼丁可能对SCVF具有治疗价值。
局限性
- 单中心研究,样本量小(SCVF 14例、IVF 19例、对照38例),结论需更大规模多中心验证。
- 研究人群均为非西班牙裔白人为主,结果外推至其他种族人群受限。
- 抗TREK-1自身抗体在SCVF中的致病机制仍需进一步功能与因果研究证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Short-coupled ventricular fibrillation (SCVF) is increasingly being recognized as a distinct primary electrical disorder and cause of otherwise unexplained cardiac arrest. However, the pathophysiology of SCVF remains largely elusive. Despite extensive genetic screening, there is no convincing evidence of a robust monogenic disease gene, thus raising the speculations for alternative pathogeneses. The role of autoimmune mechanisms in SCVF has not been investigated so far. The objective of this study was to screen for circulating autoantibodies in patients with SCVF and assess their role in arrhythmogenesis. METHODS: This is a prospective, single-center, case-control study enrolling cardiac arrest survivors diagnosed with SCVF or idiopathic ventricular fibrillation (IVF) between 2019 and 2023 at the Institut Universitaire de Cardiologie et de Pneumologie de Québec, Université Laval Inherited Arrhythmia Clinic in Canada. Plasma samples were screened for autoantibodies targeting cardiac ion channels using peptide microarray technology. Identified target autoantibodies were then purified from pooled plasma samples for subsequent cellular electrophysiological studies. RESULTS: Fourteen patients with SCVF (n=4 [29% of patients] female patients; median age, 45 years [interquartile range: 36, 59]; n=14 [100% of patients] non-Hispanic White) and 19 patients with idiopathic ventricular fibrillation (n=8 [42%] female patients; median age, 49 years [38, 57]; n=19 [100%] non-Hispanic White) were enrolled in the study and compared with 38 (n=20 [53%] female subjects; median age, 45 years [29, 66]; n=36 [95%] non-Hispanic White) sex-, age- and ethnicity-matched healthy controls. During the study period, 11 (79%) SCVF probands experienced ventricular fibrillation recurrence after a median of 4.3 months (interquartile range, 0.3-20.7). Autoantibodies targeting cardiac TREK-1 (TWIK [tandem of pore-domains in a weakly inward rectifying potassium channel]-related potassium channel 1 were identified in 7 (50%) patients with SCVF (P=0.049). Patch clamp experiments demonstrated channel-activating properties of anti-TREK-1 autoantibodies that are antagonized by quinidine in both HEK293 cells and human induced pluripotent stem cell-derived cardiomyocytes. CONCLUSIONS: Patients with SCVF harbor circulating autoantibodies against the cardiac TREK-1 channel. Anti-TREK-1 autoantibodies not only present the first reported biomarker for SCVF, but our functional studies also suggest a direct implication in the arrhythmogenesis of SCVF.
引用
- Li J, Janin A, Patoughi M, et al. Circulating Autoantibodies Targeting TREK-1 in Patients With Short-Coupled Ventricular Fibrillation. Circulation. 2024. PMID: 39315453. doi:10.1161/CIRCULATIONAHA.124.070284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。